title: Why is methotrexate the first selection in disease-modifying antirheumatic drug therapy? Comment on the article by Wolfe et al.
authors.forename: C V
authors.initials: CV
authors.lastname: Caballero-Uribe
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003105:Colombia; D004363:Drug Utilization; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D018579:Patient Selection; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012219:Rheumatology / Q000379:methods*; D011795:Surveys and Questionnaires
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate